Galenica Pharmaceuticals Shares Soar After U.S. FDA Backs Ferinject

ZURICH, Feb 4 (Reuters) - Shares in Swiss healthcare provider Galenica jumped 15 percent on Monday after a U.S. Food and Drug Administration advisory panel surprised investors by backing its Ferinject anaemia drug.

MORE ON THIS TOPIC